SRx Health Solutions Inc.
Get $10 bonus on your first $100 deposit for SRXH
Get $10 bonus on your first $100 deposit for SRXH
SRx Health Solutions Inc. (SRXH) Stock Competitors & Peer Comparison
See (SRXH) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRXH | $0.14 | +4.27% | 4.6M | -0.80 | -$0.17 | N/A |
| LLY | $935.62 | -1.98% | 884B | 40.70 | $22.99 | +0.67% |
| JNJ | $243.04 | -0.44% | 585.7B | 22.03 | $11.03 | +2.14% |
| ABBV | $208.80 | -2.88% | 369.2B | 88.10 | $2.37 | +3.18% |
| MRK | $120.87 | +0.02% | 298.8B | 16.63 | $7.27 | +2.75% |
| NVS | $154.03 | -0.68% | 297.8B | 21.54 | $7.15 | +2.00% |
| AMGN | $347.94 | -1.51% | 187.6B | 24.43 | $14.24 | +2.78% |
| GILD | $139.71 | -0.42% | 173.4B | 17.14 | $8.15 | +2.28% |
| NVO | $36.98 | +1.36% | 164.3B | 10.44 | $3.54 | +3.59% |
| PFE | $28.33 | -0.77% | 161.1B | 20.83 | $1.36 | +6.07% |
Stock Comparison
SRXH vs LLY Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, LLY has a market cap of 884B. Regarding current trading prices, SRXH is priced at $0.14, while LLY trades at $935.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas LLY's P/E ratio is 40.70. In terms of profitability, SRXH's ROE is +4.36%, compared to LLY's ROE of +0.98%. Regarding short-term risk, SRXH is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check LLY's competition here
SRXH vs JNJ Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, JNJ has a market cap of 585.7B. Regarding current trading prices, SRXH is priced at $0.14, while JNJ trades at $243.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas JNJ's P/E ratio is 22.03. In terms of profitability, SRXH's ROE is +4.36%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, SRXH is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check JNJ's competition here
SRXH vs ABBV Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, ABBV has a market cap of 369.2B. Regarding current trading prices, SRXH is priced at $0.14, while ABBV trades at $208.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas ABBV's P/E ratio is 88.10. In terms of profitability, SRXH's ROE is +4.36%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, SRXH is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check ABBV's competition here
SRXH vs MRK Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, MRK has a market cap of 298.8B. Regarding current trading prices, SRXH is priced at $0.14, while MRK trades at $120.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas MRK's P/E ratio is 16.63. In terms of profitability, SRXH's ROE is +4.36%, compared to MRK's ROE of +0.36%. Regarding short-term risk, SRXH is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check MRK's competition here
SRXH vs NVS Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, NVS has a market cap of 297.8B. Regarding current trading prices, SRXH is priced at $0.14, while NVS trades at $154.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas NVS's P/E ratio is 21.54. In terms of profitability, SRXH's ROE is +4.36%, compared to NVS's ROE of +0.33%. Regarding short-term risk, SRXH is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check NVS's competition here
SRXH vs AMGN Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, AMGN has a market cap of 187.6B. Regarding current trading prices, SRXH is priced at $0.14, while AMGN trades at $347.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas AMGN's P/E ratio is 24.43. In terms of profitability, SRXH's ROE is +4.36%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, SRXH is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check AMGN's competition here
SRXH vs GILD Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, GILD has a market cap of 173.4B. Regarding current trading prices, SRXH is priced at $0.14, while GILD trades at $139.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas GILD's P/E ratio is 17.14. In terms of profitability, SRXH's ROE is +4.36%, compared to GILD's ROE of +0.41%. Regarding short-term risk, SRXH is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GILD's competition here
SRXH vs NVO Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, NVO has a market cap of 164.3B. Regarding current trading prices, SRXH is priced at $0.14, while NVO trades at $36.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas NVO's P/E ratio is 10.44. In terms of profitability, SRXH's ROE is +4.36%, compared to NVO's ROE of +0.61%. Regarding short-term risk, SRXH is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check NVO's competition here
SRXH vs PFE Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, PFE has a market cap of 161.1B. Regarding current trading prices, SRXH is priced at $0.14, while PFE trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas PFE's P/E ratio is 20.83. In terms of profitability, SRXH's ROE is +4.36%, compared to PFE's ROE of +0.09%. Regarding short-term risk, SRXH is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check PFE's competition here
SRXH vs AZN Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, AZN has a market cap of 157.7B. Regarding current trading prices, SRXH is priced at $0.14, while AZN trades at $203.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas AZN's P/E ratio is 31.16. In terms of profitability, SRXH's ROE is +4.36%, compared to AZN's ROE of +0.23%. Regarding short-term risk, SRXH is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check AZN's competition here
SRXH vs BMY Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, BMY has a market cap of 121.4B. Regarding current trading prices, SRXH is priced at $0.14, while BMY trades at $59.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas BMY's P/E ratio is 17.23. In terms of profitability, SRXH's ROE is +4.36%, compared to BMY's ROE of +0.39%. Regarding short-term risk, SRXH is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check BMY's competition here
SRXH vs SNY Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, SNY has a market cap of 116.6B. Regarding current trading prices, SRXH is priced at $0.14, while SNY trades at $47.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas SNY's P/E ratio is 20.55. In terms of profitability, SRXH's ROE is +4.36%, compared to SNY's ROE of +0.11%. Regarding short-term risk, SRXH is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check SNY's competition here
SRXH vs GSK Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, GSK has a market cap of 114.2B. Regarding current trading prices, SRXH is priced at $0.14, while GSK trades at $56.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas GSK's P/E ratio is 15.40. In terms of profitability, SRXH's ROE is +4.36%, compared to GSK's ROE of +0.30%. Regarding short-term risk, SRXH is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GSK's competition here
SRXH vs HZNP Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SRXH is priced at $0.14, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SRXH's ROE is +4.36%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SRXH is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check HZNP's competition here
SRXH vs BIIB Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, BIIB has a market cap of 26B. Regarding current trading prices, SRXH is priced at $0.14, while BIIB trades at $177.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas BIIB's P/E ratio is 20.15. In terms of profitability, SRXH's ROE is +4.36%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, SRXH is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check BIIB's competition here
SRXH vs GRFS Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, GRFS has a market cap of 7B. Regarding current trading prices, SRXH is priced at $0.14, while GRFS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas GRFS's P/E ratio is 13.08. In terms of profitability, SRXH's ROE is +4.36%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, SRXH is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GRFS's competition here
SRXH vs OGN Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, OGN has a market cap of 1.7B. Regarding current trading prices, SRXH is priced at $0.14, while OGN trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas OGN's P/E ratio is 8.83. In terms of profitability, SRXH's ROE is +4.36%, compared to OGN's ROE of +0.26%. Regarding short-term risk, SRXH is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check OGN's competition here
SRXH vs CELG-RI Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, CELG-RI has a market cap of 243.2M. Regarding current trading prices, SRXH is priced at $0.14, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, SRXH is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check CELG-RI's competition here
SRXH vs SCLX Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, SCLX has a market cap of 63.6M. Regarding current trading prices, SRXH is priced at $0.14, while SCLX trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas SCLX's P/E ratio is -0.18. In terms of profitability, SRXH's ROE is +4.36%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, SRXH is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check SCLX's competition here
SRXH vs CTOR Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, CTOR has a market cap of 62.1M. Regarding current trading prices, SRXH is priced at $0.14, while CTOR trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas CTOR's P/E ratio is -2.27. In terms of profitability, SRXH's ROE is +4.36%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, SRXH is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check CTOR's competition here
SRXH vs MIRA Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, MIRA has a market cap of 46.5M. Regarding current trading prices, SRXH is priced at $0.14, while MIRA trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas MIRA's P/E ratio is -0.82. In terms of profitability, SRXH's ROE is +4.36%, compared to MIRA's ROE of -6.46%. Regarding short-term risk, SRXH is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check MIRA's competition here
SRXH vs SCLXW Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, SCLXW has a market cap of 1.1M. Regarding current trading prices, SRXH is priced at $0.14, while SCLXW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas SCLXW's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, SRXH is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check SCLXW's competition here
SRXH vs CRXT Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SRXH is priced at $0.14, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SRXH's ROE is +4.36%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SRXH is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check CRXT's competition here
SRXH vs BDSIW Comparison April 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.6M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SRXH is priced at $0.14, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.80, whereas BDSIW's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SRXH is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check BDSIW's competition here